Watch time: 4 minutes
“Seeking to expand the use of people’s knowledge and quality improvement methodologies, we are pleased to join in 2023 and beyond.”
Epilepsy treatment has advanced further by using the healthcare system to track patients and their health. However, gaps still remain in the documentation of patient data. Creating patient documentation in a more effective way and sharing it with other centers to effectively prescribe patient care will allow for more individualized care and improved outcomes for patients with epilepsy. It can lead to improved and higher quality care.
There are some exciting ongoing trials that could lead to FDA approval in 2023, said Anup Patel, M.D., Ph.D. In addition, he adds, progress is being made in certain types of gene therapy in other neurological conditions besides epilepsy, such as spinal muscular atrophy and Duchenne muscular dystrophy.
in a recent interview with neurology live®Patel, a pediatric neurologist at Nationwide Children’s Hospital, spoke about current gaps in epilepsy treatment. Patel, a professor of clinical pediatrics and neurology at Nationwide Children’s Hospital and The Ohio State University School of Medicine, also spoke about her expectations in the coming months regarding treatment approvals and ongoing clinical trials. .
